Naz Rahman
Stock Analyst at Maxim Group
(0.35)
# 4,309
Out of 5,172 analysts
38
Total ratings
21.21%
Success rate
-39.91%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $575 | $454.00 | +26.65% | 2 | Mar 18, 2026 | |
| NXGL NEXGEL | Maintains: Buy | $6 → $2 | $0.69 | +191.93% | 2 | Mar 12, 2026 | |
| SCNX Scienture Holdings | Initiates: Buy | $1.5 | $0.48 | +212.50% | 1 | Feb 24, 2026 | |
| KZIA Kazia Therapeutics | Maintains: Buy | $15 → $20 | $7.48 | +167.38% | 1 | Oct 2, 2025 | |
| AYTU Aytu BioPharma | Maintains: Buy | $9 → $7 | $2.61 | +168.20% | 2 | Sep 25, 2025 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $0.60 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $8.23 | +106.56% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $135 → $75 | $1.22 | +6,047.54% | 2 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $32.33 | +116.52% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $0.75 | - | 2 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $7.38 | - | 4 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $8 | $1.89 | +323.28% | 7 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.28 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $13.37 | +236.57% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $7.94 | +1,663.00% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.32 | - | 3 | Nov 17, 2023 |
Vertex Pharmaceuticals
Mar 18, 2026
Upgrades: Buy
Price Target: $575
Current: $454.00
Upside: +26.65%
NEXGEL
Mar 12, 2026
Maintains: Buy
Price Target: $6 → $2
Current: $0.69
Upside: +191.93%
Scienture Holdings
Feb 24, 2026
Initiates: Buy
Price Target: $1.5
Current: $0.48
Upside: +212.50%
Kazia Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $7.48
Upside: +167.38%
Aytu BioPharma
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $2.61
Upside: +168.20%
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.60
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $8.23
Upside: +106.56%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $135 → $75
Current: $1.22
Upside: +6,047.54%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $32.33
Upside: +116.52%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.75
Upside: -
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $7.38
Upside: -
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $1.89
Upside: +323.28%
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.28
Upside: -
Jul 26, 2024
Initiates: Buy
Price Target: $45
Current: $13.37
Upside: +236.57%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $7.94
Upside: +1,663.00%
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.32
Upside: -